Application 090195
- Type
- ANDA
- Sponsor
- LEADING PHARMA LLC
Application Products#
Product, Drug, Ingredient table| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|
| 001 | GLYCOPYRROLATE | GLYCOPYRROLATE | TABLET;ORAL | 1MG | No | No |
| 002 | GLYCOPYRROLATE | GLYCOPYRROLATE | TABLET;ORAL | 2MG | No | No |
NDC Listings For This Application#
NDC, Name, Nonproprietary name table| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|
| 0904-6521 | Glycopyrrolate | Glycopyrrolate | Major Pharmaceuticals | ANDA | Current |
| 42291-303 | Glycopyrrolate | Glycopyrrolate | AvKARE, Inc. | ANDA | Current |
| 42291-303 | Glycopyrrolate | Glycopyrrolate | AvKARE | ANDA | Current |
| 42291-304 | Glycopyrrolate | Glycopyrrolate | AvKARE, Inc. | ANDA | Current |
| 42291-304 | Glycopyrrolate | Glycopyrrolate | AvKARE | ANDA | Current |
| 64125-139 | Glycopyrrolate | Glycopyrrolate | Excellium Pharmaceutical, Inc. | ANDA | Current |
| 64125-140 | Glycopyrrolate | Glycopyrrolate | Excellium Pharmaceutical, Inc. | ANDA | Current |
| 69315-139 | Glycopyrrolate | Glycopyrrolate | Leading Pharma, LLC | ANDA | Current |
| 69315-139 | Glycopyrrolate | Glycopyrrolate | Leading Pharma, LLC | ANDA | Current |
| 69315-139 | Glycopyrrolate | Glycopyrrolate | Leading Pharma, LLC | ANDA | Current |
| 69315-139 | Glycopyrrolate | Glycopyrrolate | Leading Pharma, LLC | ANDA | Current |
| 69315-140 | Glycopyrrolate | Glycopyrrolate | Leading Pharma, LLC | ANDA | Current |
| 69315-140 | Glycopyrrolate | Glycopyrrolate | Leading Pharma, LLC | ANDA | Current |
| 69315-140 | Glycopyrrolate | Glycopyrrolate | Leading Pharma, LLC | ANDA | Current |
| 69315-140 | Glycopyrrolate | Glycopyrrolate | Leading Pharma, LLC | ANDA | Current |
| 71335-0020 | Glycopyrrolate | Glycopyrrolate | Bryant Ranch Prepack | ANDA | Current |
| 71335-0020 | Glycopyrrolate | Glycopyrrolate | Bryant Ranch Prepack | ANDA | Current |
| 71335-0020 | Glycopyrrolate | Glycopyrrolate | Bryant Ranch Prepack | ANDA | Current |